FY2025 · period end Jun '25 · from the 10-K filed Oct 8, 2025
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Jun '25 | FY24Jun '24 |
|---|---|---|
| Revenue | — | — |
| Gross Profit | — | — |
| Operating Income | — | — |
| Net Income | negative: -$0.00B | negative: -$0.00B |
| EPS (Diluted) | negative: -$0.16 | negative: -$0.14 |
| Metric | FY25Jun '25 | FY24Jun '24 |
|---|---|---|
| Total Assets | $0.01B | $0.00B |
| Total Liabilities | $0.01B | $0.00B |
| Stockholders' Equity | $0.00B | $0.00B |
| Cash & Equivalents | — | — |
| Total Debt | — | — |
| Metric | FY25Jun '25 | FY24Jun '24 |
|---|---|---|
| Operating Cash Flow | negative: -$0.01B | negative: -$0.00B |
| Capital Expenditures | $0.00B | $0.00B |
| Free Cash Flow | negative: -$0.01B | negative: -$0.00B |
| Metric | FY25Jun '25 | FY24Jun '24 |
|---|---|---|
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Return on Equity | negative: -126.8% | negative: -167.3% |
| Return on Assets | negative: -59.4% | negative: -62.4% |
| Debt / Equity | — | — |
Showing the most recent 2 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Who is buying and selling Advanced Biomed Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ADVB yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on ADVB and publish the result to your public profile.
Ask about Advanced Biomed Inc.
Continue in Workspace — cited answers on ADVB, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001213900-26-057226 | Mar 31, 2026 | May 15, 2026 | May 15, 2026 13:28 UTC | EDGAR |
| 10-Q | 0001213900-26-016458 | Dec 31, 2025 | Feb 13, 2026 | Feb 13, 2026 21:31 UTC | EDGAR |
| 10-Q | 0001213900-25-112602 | Sep 30, 2025 | Nov 19, 2025 | Nov 19, 2025 21:01 UTC | EDGAR |
| 10-K | 0001213900-25-097465 | Jun 30, 2025 | Oct 8, 2025 | Oct 8, 2025 21:00 UTC | EDGAR |
| 10-Q | 0001213900-25-044148 | Mar 31, 2025 | May 15, 2025 | May 15, 2025 20:01 UTC | EDGAR |
| 10-Q | 0001213900-25-032066 | Dec 31, 2024 | Apr 15, 2025 | Apr 15, 2025 20:01 UTC | EDGAR |
Direct links to SEC EDGAR. ADVB has additional filings available on the SEC site.
6 numbers Advanced Biomed Inc. later changed — same XBRL tag, both filings linked.
Liabilities·As of Jun 30, 2025
Major restatementwas$3M
Revised up in a 10-Q.
Assets·As of Jun 30, 2025
Major restatementwas$6.5M
Revised up in a 10-Q.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2024
Major restatementwas-$907.9K
Revised up in a 10-Q.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q3 2025
Major restatementwas-$1.4M
Revised up in a 10-Q.
Liabilities, Current·As of Jun 30, 2025
Major restatementwas$2.9M
Revised up in a 10-Q.
Assets, Current·As of Jun 30, 2025
Major restatementwas$6M
Revised up in a 10-Q.
ADVB is not the only one.
See every restatement we've found across the market — or get an alert the next time ADVB revises a number.
Restatements are detected by comparing every vintage of a fact across all of Advanced Biomed Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ADVB's most significant revisions, and a figure absent from it has not been certified as unrevised.
